DelveInsight's "RNAi Technology Market Insights and Market Forecast - 2034" report offers a comprehensive view of market trends across North America, Europe, Asia-Pacific, and the Rest of World, tracing both historical performance and forward-looking projections.

Key Takeaways from the RNAi Technology Market Report

The market stood at approximately USD 1.65 billion in 2025 and is expected to climb to USD 5.55 billion by 2034, reflecting a 14.4% CAGR between 2026 and 2034.
siRNA remained the leading molecule type, capturing 68% of the market in 2025, as it forms the basis of nearly every approved RNAi therapeutic and late-stage clinical candidate.
Drug discovery and development was the top application, representing 69% of the market in 2025, underscoring RNAi's central role in identifying and validating therapeutic targets.
GalNAc conjugates led delivery technologies with a 46% share in 2025, having reshaped liver-directed delivery through convenient, infrequent subcutaneous dosing.
Pharmaceutical and biotechnology companies made up 64% of the end-user segment in 2025, reflecting their outsized role in developing, manufacturing, and commercializing RNAi medicines.
North America held the largest regional share at 45% of global revenue in 2025, while Asia-Pacific, led by China, is advancing at the fastest pace.
Alnylam Pharmaceuticals secured FDA approval in March 2025 for AMVUTTRA (vutrisiran) in the cardiomyopathy of transthyretin-mediated amyloidosis, marking the first RNAi therapy proven to lower cardiovascular death, hospitalization, and urgent heart failure visits.
Novartis AG entered a cardiovascular RNAi collaboration with Shanghai Argo in September 2025 valued at up to USD 4.165 billion.
Companies active in this space include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk A/S (Dicerna), Silence Therapeutics, Novartis AG, Ionis Pharmaceuticals, Thermo Fisher Scientific, Merck KGaA, Sirnaomics, and Sanofi S.A., among others.

RNAi Technology Market Segmentation Overview

By Molecule Type: siRNA, miRNA, shRNA, Others
By Application: Drug Discovery and Development, Therapeutics, Functional Genomics
By Delivery Technology: GalNAc Conjugates, Lipid Nanoparticles, Polymer and Other Carriers, Viral Vectors
By Therapeutic Area: Rare Genetic Disorders, Cardiometabolic Disorders, Oncology, Hepatic and Infectious Diseases, Neurological and Other Disorders
By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research and Manufacturing Organizations

RNAi Technology Pipeline Momentum

The RNAi Technology Pipeline has broadened well beyond its original focus on hepatic disease, now spanning candidates aimed at rare genetic disorders, cardiometabolic conditions, oncology, and infectious disease. Arrowhead Pharmaceuticals' completion of phase 2 testing for ARO-HIF2 in renal cell carcinoma, and Sirnaomics' venture into aesthetic-medicine applications, show how far the pipeline has extended past its liver-focused beginnings.

RNAi Technology Market Outlook

RNA interference works by using small RNA molecules to regulate gene expression, degrading or blocking specific messenger RNA sequences so that disease-associated proteins are never produced. This mechanism, delivered through siRNA, miRNA, and shRNA, allows genes once thought undruggable by conventional small molecules or antibodies to be silenced directly. Use of the technology spans two areas: therapeutic treatment of rare genetic, cardiometabolic, and hepatic conditions, and research applications that support drug discovery, target validation, and functional genomics. Delivery platforms such as GalNAc conjugates and lipid nanoparticles have been central to this progress, resolving earlier problems with instability, poor cellular uptake, and off-target activity.

RNAi Technology

Momentum in the sector stems from a growing roster of approved siRNA medicines, now numbering more than ten, paired with delivery advances and a clinical pipeline that has surpassed 150 active interventional trials. Large-scale partnerships, such as Novartis' multi-billion-dollar tie-up with Shanghai Argo and Novo Nordisk's acquisition of Dicerna, are pulling major pharmaceutical players deeper into the field. At the same time, extending delivery beyond the liver, managing high development costs, and navigating still-evolving regulatory pathways remain factors that slow the pace of expansion.

Even so, growing recognition of RNAi Technology as a validated, commercially significant platform continues to draw fresh investment and broaden its application beyond rare diseases into larger patient populations, and closer study of RNAi Technology Epidemiology patterns alongside rising chronic and genetic disease burden helps clarify where future demand for these therapies and research tools is likely to concentrate.

Scope of the Report

Coverage- Global
Study Period- 2023-2034
RNAi Technology Companies - Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk A/S (Dicerna), Silence Therapeutics, Novartis AG, Ionis Pharmaceuticals, Thermo Fisher Scientific, Merck KGaA, Sirnaomics, and Sanofi S.A., and others.
Segments Covered- Molecule Type, Application, Delivery Technology, Therapeutic Area, End User
Market Dynamics Covered- Drivers and Restraints

Latest Reports offered by Delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

RNAi Technology Market on Track for Strong Global Expansion

Companies active in this space include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk A/S (Dicerna), Silence Therapeutics, Novartis AG, Ionis